Evidence map›Paper›PMID 35814389›Full record

ArticleFrontiers in oncology2022

Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes.

Arlindo A Moura, Maria Julia B Bezerra, Aline M A Martins, Daniela P Borges, Roberta T G Oliveira, Raphaela M Oliveira, Kaio M Farias, Arabela G Viana, Guilherme G C Carvalho, Carlos R K Paier and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Arlindo A MouraGraduate Program in Animal Science, Federal University of Ceará, Fortaleza, Brazil.
Maria Julia B BezerraGraduate Program in Animal Science, Federal University of Ceará, Fortaleza, Brazil.
Aline M A MartinsLaboratory of Protein Chemistry and Biochemistry, The University of Brasília, Brasília, Brazil.
Daniela P BorgesDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Roberta T G OliveiraDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Raphaela M OliveiraLaboratory of Protein Chemistry and Biochemistry, The University of Brasília, Brasília, Brazil.
Kaio M FariasDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Arabela G VianaGraduate Program in Animal Science, Federal University of Ceará, Fortaleza, Brazil.
Guilherme G C CarvalhoDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Carlos R K PaierDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Marcelo V SousaLaboratory of Protein Chemistry and Biochemistry, The University of Brasília, Brasília, Brazil.
Wagner FontesLaboratory of Protein Chemistry and Biochemistry, The University of Brasília, Brasília, Brazil.
Carlos A O RicartLaboratory of Protein Chemistry and Biochemistry, The University of Brasília, Brasília, Brazil.
Maria Elisabete A MoraesDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Silvia M M MagalhãesDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Cristiana L M FurtadoDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Manoel O Moraes-FilhoDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Claudia PessoaDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Ronald F PinheiroDrug Research and Development Center (NPDM), The School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Universidade Federal do Ceará · BRUniversidade de Brasília · BRUniversidade de Fortaleza · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a hematological disorder characterized by abnormal stem cell differentiation and a high risk of acute myeloid leukemia transformation. Treatment options for MDS are still limited, making the identification of molecular signatures for MDS progression a vital task. Thus, we evaluated the proteome of bone marrow plasma from patients (n = 28) diagnosed with MDS with ring sideroblasts (MDS-RS) and MDS with blasts in the bone marrow (MDS-EB) using label-free mass spectrometry. This strategy allowed the identification of 1,194 proteins in the bone marrow plasma samples. Polyubiquitin-C (UBC), moesin (MSN), and Talin-1 (TLN1) showed the highest abundances in MDS-EB, and centrosomal protein of 55 kDa (CEP55) showed the highest relative abundance in the bone marrow plasma of MDS-RS patients. In a follow-up, in the second phase of the study, expressions of

Indexed as

bone marrowcentrosomal protein of 55 kDa (CEP55)karyotypemyelodysplastic syndromeproteomicsTalin-1 (TLN1)

Identifiers

PMID35814389
PMCPMC9257025
OpenAlexW4283378852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.